More than half of surveyed IT professionals said monitoring data cost more than the infrastructure being watched, while many struggled to measure AI performance
PerturbAI, an AI-native biotechnology company, today announced results from its year-long collaboration with OpenAI to advance biomedical research and drug discovery. Working with Scripps Research, the teams developed an AI reasoning framework that helps scientists interpret large experimental datasets,